Trials / Completed
CompletedNCT00654628
Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients (0653A-172)(COMPLETED)
Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 173 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 20 Years – 79 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of ezetimibe/simvastatin in patients newly diagnosed with dyslipidemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ezetimibe (+) simvastatin | Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks. |
Timeline
- Start date
- 2007-08-01
- Primary completion
- 2009-07-01
- Completion
- 2009-07-01
- First posted
- 2008-04-08
- Last updated
- 2024-05-22
- Results posted
- 2010-08-26
Source: ClinicalTrials.gov record NCT00654628. Inclusion in this directory is not an endorsement.